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AN EVALUATION OF PHARMACEUTICAL PRICES UNDER THE
PHARMACEUTICAL FEDERAL SUPPLY SCHEDULE
Bhandary D1, Malone DC2
1University of Arizona,Tucson, AZ, USA; 2University of Arizona
College of Pharmacy,Tucson, AZ, USA
OBJECTIVES: To evaluate the impact of the Veterans Health
Care Act in limiting the price of pharmaceutical drugs to 76%
of the non-federal average manufacturer price for the Big 4
federal agencies (VA, Department of Defense, Coast Guard, and
Public Health Services). METHODS: Estimated wholesale ac-
quisition cost (WAC), used as a surrogate for the non-federal
average manufacturer price, was obtained from First DataBank,
while FSS price for the Big 4 federal agencies was obtained from
the VA pharmaceutical beneﬁt management. The federal dis-
count was calculated as the ratio, Big 4/WAC. Sub-analyses were
also conducted for therapeutic classes consisting of only single-
source products and for brand-name manufacturers with more
than 100 products in the combined database. RESULTS: A total
of 8877 unique products met the inclusion criteria for the study.
The products belonged to 529 unique medication classes and
were manufactured by 225 unique manufacturers. Nearly 94%
of all the products had a Big 4 price less than 76% of the esti-
mated WAC (mean ± SD = 50% ± 21%). Therapeutic categories
with only one product on average had a 39% federal discount
while therapeutic categories with more than 6 products received
on average 51% federal discount. Discounts for single source
products were lower than the entire basket of products. None of
the manufacturers had a mean Big 4 price across all products
more than the 76% of the estimated WAC, with the lowest being
47% and the highest at 63%. CONCLUSION: The results
suggest that the Veterans Health Care Act was successful in lim-
iting the price of pharmaceuticals to 76% of the estimated WAC.
Further, it is also evident that ﬁrms had discounts larger than the
mandated level.
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FINANCIAL IMPACT OF A PRIOR-AUTHORIZATION
RESTRICTION FOR PIMECROLIMUS 1% CREAM IN THE
TREATMENT OF ATOPIC DERMATITIS
Mahajan S1, Chang J1, Sung J2
1Duke Clinical Research Institute, Durham, NC, USA; 2Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA
Health plans impose drug prior-authorization (PA) programs as
a way to control budget which may lead to adverse health-
consequences by restricting patients’ medication access. Addi-
tionally, it increases plan administrative costs. OBJECTIVE: This
study examines the 1-year ﬁnancial impact of PA restriction on
pimecrolimus use among atopic dermatitis (AD) patients from a
plan’s perspective. METHODS: PA’s ﬁnancial impact was calcu-
lated by estimating annual cost differences with and without PA.
Total plan costs with PA included PA administration and med-
ication costs, while costs without PA comprised medication costs
alone. Model-inputs included estimates of AD prevalence and
pimecrolimus utilization from MarketScan database, 2003; PA
acceptance rate and coinsurance/copayment from Pharmacy
Beneﬁt Report 2004; PA costs from published literature and
pimecrolimus costs from 2004 wholesale acquisition costs.
Annual medication costs included costs and utilization of pime-
crolimus minus tier-speciﬁc co-payment/coinsurance, assuming
second- and third-tier placements for pimecrolimus with and
without PA, respectively. A 20% increase in pimecrolimus users
and migration towards larger tube sizes was assumed after lifting
PA. Sensitivity analyses were performed on AD prevalence, costs
of PA administration, medications. RESULTS: Estimated AD
prevalence was 2.89%, of which 8.36% were pimecrolimus
users. Assuming a 1,000,000-member plan, this resulted in 2416
PA requests at a cost of $20 each. The PA acceptance rate 
was 73.9% (or 1785 approved users). Total costs with PA 
were $178,840 (PA administration, $48,321; medication costs,
$130,519) or $0.0149 per member per month (PMPM). After
lifting PA, despite 20% increase in pimecrolimus utilization, 
total costs were $128,029 ($0.0107 PMPM) generating savings
of $50,811 ($0.0042 PMPM). In sensitivity analyses, savings
(losses) from lifting PA ranged from $0.0083 PMPM to
($0.0030) PMPM. CONCLUSIONS: Based on PA administra-
tive costs and pimecrolimus utilization, PA restriction is not cost-
efﬁcient for health plans. These analyses provide a reference 
for decision-makers to project expected spending for their 
population.
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IN1
COMPARISON OF RISK FACTORS FOR BLOOD STREAM
CANDIDEMIA AND BACTEREMIA IN HOSPITALIZED
PATIENTS
Amrutkar PP, Rege M, Kumar N, Kachroo S, Garey KW
University of Houston, College of Pharmacy, Houston,TX, USA
OBJECTIVE: Antifungal therapy is often not given as empiric
therapy in patients with suspected nosocomial blood stream
infections (BSI). This is likely due to the fact that identiﬁcation
of risk factors for speciﬁc pathogens (candida vs. bacteria) is dif-
ﬁcult. The purpose of this study was to identify risk factors that
would predict those patients most at risk for candidemia com-
pared to bacteremia. METHODS: Retrospective cohort study to
distinguish risk factors for BSI due to candida or bacteria in hos-
pitalized patients. Clinical data was collected from the medical
charts of patients hospitalized between 2002–2004 with their
ﬁrst documented episode of bloodstream candidemia or bac-
teremia. Univariate analysis was conducted to evaluate individ-
ual effects of variables. All variables having a signiﬁcance level
of less than 0.2 were then added to the multivariate logistic
regression model to determine risk factors for candidemia and
bacteremia. RESULTS: A total of 164 patients were evaluated
for the study. In univariate analysis, risk factors for candidemia
included Total Parental Nutrition (TPN) use (OR = 5.92, p =
0.001), corticosteroids (OR = 2.60, p = 0.0109), or ICU location
(OR = 3.44, p = 0.0002). Risk factors for bacteremia included
renal disease (OR = 0.498, p = 0.028), non-abdominal surgery
(OR = 0.369, p = 0.0936), pulmonary disease (OR = 0.242, p =
0.0001), and cardiovascular disease (OR = 0.187, p = 0.0001).
In the multivariate model, ICU location, pulmonary disease,
cardio-vascular disease, and TPN use (p < 0.01 for all variables)
were independent predictors of risk factors associated with bac-
teremia or candidemia. CONCLUSION: ICU location, TPN use,
and types of medical disorders were able to help distinguish
patients with candidemia compared to bacteremia. The results
of this study can help to choose appropriate empiric therapy in
patients with BSI.
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SIMULATION OF A PROPOSED TRIAL TO EVALUATE THE
COST-EFFECTIVENESS OF USING A COMBINATION REGIMEN
FOR THE TREATMENT OF ACUTE SINUSITIS
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